Pertussis, 2006

Introduction, 2006

Table 1: List of Reportable Diseases, 2006

Table 2: Cases of Selected Communicable Diseases Reported, 2006

During 2006, 320 cases of pertussis (6.2 per 100,000) were reported in Minnesota, following a peak of 1,571 cases reported in 2005. Laboratory confirmation was available for 209 (65%) cases, 39 (19%) of which were confirmed by culture and 170 (81%) of which were confirmed by PCR. In addition to the laboratory-confirmed cases, 49 (15%) cases were epidemiologically linked to laboratory-confirmed cases, and 62 (19%) met a clinical case definition. One hundred sixty-three (51%) of the reported cases occurred in residents of the metropolitan area.

Paroxysmal coughing is the most commonly reported symptom. Three hundred (94%) of the case-patients experienced paroxysmal coughing. About one third (97, 30%) reported whooping. Although commonly referred to as “whooping cough,” very young children, older individuals, and persons previously immunized may not have the typical “whoop” associated with pertussis. Post-tussive vomiting was reported in 154 (48%) of the cases. Infants and young children are at the highest risk for severe disease and complications. Pneumonia was diagnosed in 14 (4%) case-patients, three (21%) of whom were less than 18 months of age. Thirteen (4%) case-patients were hospitalized; eight (62%) of the hospitalized patients were younger than 6 months of age.

Due to waning of immunity from either natural infection or vaccine, pertussis can affect persons of any age. The disease is increasingly recognized in older children and adults. During 2006, case-patients ranged in age from 1 month to 89 years. One hundred twelve (35%) cases occurred in adolescents 13 to 17 years of age; 91 (28%) cases occurred in adults 18 years of age and older; 64 (20%) occurred in children 5-12 years of age; 32 (10%) occurred in children 6 months through 4 years of age, and 20 (6%) occurred in infants less than 6 months of age. Age was unknown for one case.

Infection in older children and adults may result in exposure of unprotected infants who are at risk for the most severe consequences of infection. During 2006, 24 pertussis cases were reported in infants less than 1 year of age. A likely source of exposure was identified for 14 (58%) cases; six (25%) of the 24 infant cases were infected by adults 18 years of age and older, one (4%) was infected by a child 13 years of age or older, and seven (29%) were infected by a child less than 13 years of age. Ten (42%) of the 24 infant cases had no identified source of infection. For these cases, the source of infection was likely outside the household. One death was reported in a 1-month-old with no underlying medical conditions. The likely source of infection was a caregiver with an undiagnosed prolonged cough illness.

Although unvaccinated children are at highest risk for pertussis, fully immunized children may also develop disease. Disease in those previously immunized is usually mild. Efficacy for currently licensed vaccines is estimated to be 71 - 84% in preventing serious disease. Of the 38 case-patients who were 7 months to 6 years of age, 19 (50%) were known to have received at least a primary series of three doses of DTP/DTaP vaccine prior to onset of illness, two (5%) received fewer than three doses and were considered preventable cases, and 17 (45%) cases in this age group had unknown vaccine history.

MDH reporting rules require that clinical isolates of Bordetella pertussis be submitted to the Public Health Laboratory. Of the 39 culture-confirmed cases, 38 (97%) of the isolates were received and sub-typed by PFGE and tested for antibiotic susceptibility to erythromycin, ampicillin, and trimethoprim-sulfamethoxazole. Eleven distinct PFGE patterns were identified; four of these patterns occurred in only a single case isolate. The two most common patterns identified accounted for 17 (45%) of the total isolates and they occurred throughout the year.

No cases of erythromycin-resistant B. pertussis have been identified in Minnesota since the first case was identified in October 1999. Statewide, all 1,194 other isolates tested to date have had low minimum inhibitory concentrations, falling within the reference range for susceptibility to the antibiotics evaluated. Only eight other erythromycin-resistant B. pertussis cases have been identified to date in the United States.

Laboratory tests should be performed on all suspected cases of pertussis. Culture of B. pertussis requires inoculation of nasopharyngeal mucous on special media and incubation for 7 to 10 days. However, B. pertussis is rarely identified late in the illness; therefore, a negative culture does not rule out disease. A positive PCR result is considered confirmatory in patients with a 2-week history of cough illness. PCR can detect non-viable organisms. Consequently, a positive PCR result does not necessarily indicate current infectiousness. Patients with a 3-week or longer history of cough illness, regardless of PCR result, may not benefit from antibiotic therapy. Cultures are necessary for molecular and epidemiologic studies and for drug susceptibility testing. Whenever possible, culture should be done in conjunction with PCR testing. Direct fluorescent antibody (DFA), provides a rapid presumptive diagnosis of pertussis; however, because both false-positive and false-negative results can occur, DFA tests should not be relied upon solely for laboratory confirmation. Serological tests are not standardized and are not acceptable for laboratory confirmation.

Two pertussis-containing vaccines (both of which combine tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine [Tdap] products) were licensed in 2005: Boostrix® (GlaxoSmithKline Biologicals), licensed for persons ages 10 through 18 years; and AdacelTM (sanofi pasteur), licensed for persons ages 11 through 64 years. These vaccines will help to decrease the incidence and transmission of pertussis in the community. The national Advisory Committee on Immunization Practices recommends Tdap vaccination in adolescents and adults through age 64 years in place of a regularly scheduled tetanus and diphtheria toxoids (Td) booster. Detailed information is at: http://www.cdc.gov/nip/vaccine/tdap/tdap_acip_recs.pdf.

Updated Monday, August 12, 2013 at 11:57AM